{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-22-000248","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.250488+00:00","generated_at":"2026-06-22T19:47:34.473435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lilly Q3 2022: revenue up 2% to $6.94B, reported EPS $1.61 (+32%), Mounjaro launch strong","bullets":["Revenue $6,941.6M (+2% reported, +7% constant currency); total volume +14%.","Reported EPS $1.61 (+32%); non-GAAP EPS $1.98 (+12%); both inclusive of $0.06 acquired IPR&D charges.","Mounjaro U.S. revenue $97.3M in first full quarter; plus $86.0M from Japan collaboration agreement.","Key growth products (Verzenio, Trulicity, Mounjaro, etc.) grew 19% and represented 70% of revenue (ex-COVID antibodies).","2022 EPS guidance updated: reported $6.50-$6.65, non-GAAP $7.70-$7.85, inclusive of $0.67 charges."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-22-000248","json":"https://secwatch.observer/filing/0000059478-22-000248.json","markdown":"https://secwatch.observer/filing/0000059478-22-000248.md","text":"https://secwatch.observer/filing/0000059478-22-000248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/0000059478-22-000248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/lly-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:47:34.473435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8182b0b7a13485d813276f50eff95ba550563aef","claim":"ELI LILLY & Co reported the third quarter of 2022 results: revenue $6,941.6, net income 1,451.7, EPS $1.61.","evidence_excerpt":"other important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Third Quarter % 2022 2021 Change Revenue $6,941.6 $6,772.8 2% Net Income – Reported 1,451.7 1,110.1 31% EPS – Reported 1.61 1.22 32% Net Income – Non-GAAP 1,789.2 1,614.2 11% EPS – Non-GAAP 1.98 1.77 12% A discussion of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/0000059478-22-000248-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$6,941.6"},{"label":"Net income","value":"1,451.7"},{"label":"EPS","value":"$1.61"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}